Abstract:Abstract Importance: Largest analysis combining clinical trial and real-world data (RWD) to assess the clinical utility of biomarkers for anti-PD-1/PD-L1 checkpoint inhibitors (CPI) in NSCLC patients. Objective: To assess the association between tumor PD-L1, TMB and blood analytes with clinical outcomes in patients with advanced NSCLC following CPI therapy. Design: Retrospective cohort study with patients stratified into high and low biomarker groups. Correlation with treatment outcome in the different biomarker groups was investigated and compared between patients treated with CPI versus chemotherapy. Setting: Data derived from electronic health records mostly from community oncology settings were combined with clinical trial data. Participants: Starting with 71850 patients with advanced NSCLC who received CPI or chemotherapy, we selected 24152 patients from an electronic health record-derived de-identified NSCLC clinicogenomic database (CGDB) from a real-world cohort and nine Roche atezolizumab trials. Patients were diagnosed between January 2011 and February 2020 (data collection cut-off date). Main Outcomes and Measures: Drug response was assessed by RECIST criteria for clinical trials and real-world response for RWD. Durable response was defined as having CR/PR without progression during the study period of 270 days. Associations of biomarker levels with treatment outcomes were analyzed using Fisher’s exact test. Results: High expression of PD-L1 on tumors (≥50%) were associated with lower risk of resistance to CPI (odds ratio [OR] 0.21; 95% CI = 0.14, 0.32; P< .001). The association was stronger in patients who had prior chemotherapy than first line CPI, with non-squamous than squamous histology, and smokers than non-smokers. Higher TMB (≥9.57 mut/Mb) was also associated with durable response (OR = 0.41; CI = 0.30, 0.55; P< .001). The combination of high TMB and PD-L1 expression was the strongest predictor of durable response (OR = 0.04; CI = 0.00, 0.20; P< .001). There was no evidence of an association between PD-L1/TMB and response to chemotherapy, suggesting a CPI-specific predictive effect. In contrast, blood analytes were prognostic, having correlation with clinical outcome irrespective of treatment type. Conclusion: This study supports the predictive utility of PD-L1 expression and TMB for NSCLC patients receiving CPI therapy and further elucidates their utility in patient sub-populations. Citation Format: WeiQing Venus So, David Dejardin, Eva Rossmann, Jehad Charo. Predictive biomarkers for PD-1 and PD-L1 checkpoint inhibitor response in NSCLC: An analysis of clinical trial and real-world data. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 5464.

Assessment of PD-L1 Expression on Circulating Tumor Cells for Predicting Clinical Outcomes in Patients with Cancer Receiving PD-1/PD-L1 Blockade Therapies.

Abstract P5-02-12: Prognostic relevance of PD-L1 expression on circulating tumor cells in metastatic breast cancer patients treated with anti-PD-1 immunotherapy

CD57+CD8+T Cells and Response to PD-1/PD-L1 Blockade in Patients with NSCLC

Meta-Analysis of Circulating Tumor Cell PD-L1 Expression and the Association with Clinical Outcomes in Non-Small Cell Lung Cancer

Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer

Detection of PD-L1 Expression and Its Clinical Significance in Circulating Tumor Cells from Patients with Non-Small-Cell Lung Cancer

The Clinical Application of Circulating Tumor Cells (ctcs) for Immunotherapy in Advanced Pancreatic Cancer.

Dynamic monitoring of PD‐L1 and Ki67 in circulating tumor cells of metastatic non‐small cell lung cancer patients treated with pembrolizumab

Clinical Implications of Aberrant PD-1 and CTLA4 Expression for Cancer Immunity and Prognosis: A Pan-Cancer Study

Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors

Circulating Tumor Cell PD-L1 Expression as Biomarker for Therapeutic Efficacy of Immune Checkpoint Inhibition in NSCLC

Immunological profiling for short-term predictive analysis in PD-1/PD-L1 therapy for lung cancer

Efficacy relevance of PD-L1 expression on circulating tumor cells in metastatic breast cancer patients treated with anti-PD-1 immunotherapy

Predictive biomarkers for PD-1/PD-L1 checkpoint inhibitor response in NSCLC: an analysis of clinical trial and real-world data

Abstract 5464: Predictive biomarkers for PD-1 and PD-L1 checkpoint inhibitor response in NSCLC: An analysis of clinical trial and real-world data

PD-L1 Expression in Circulating Tumor Cells Increases during Radio(chemo)therapy and Indicates Poor Prognosis in Non-small Cell Lung Cancer

CD69 and SBK1 as potential predictors of responses to PD-1/PD-L1 blockade cancer immunotherapy in lung cancer and melanoma

Comparative Analysis of Predictive Biomarkers for PD-1/PD-L1 Inhibitors in Cancers: Developments and Challenges

Predictive value of the biomarker of peripheral blood of NSCLC patients responding to anti-PD-1 treatment

Tumor Infiltrating Lymphocyte Expression of PD-1 Predicts Response to Anti-PD-1/PD-L1 Immunotherapy

Cmar_a_245425 2069..2078